Vanta Bioscience Ltd

Vanta Bioscience Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Vanta Bioscience Ltd

₹ 29.8 -4.98%
24 Jul - close price
vantabio.com BSE - SME: 540729
About

Incorporated in 2016, Vanta Bioscience
Ltd is in the business of Preclinical Activities.[1]

Key Points

Business Overview:[1]
The company is a preclinical contract research organization, offering preclinical safety assessment services for clientele from the Pharmaceutical, Medical Devices, Nutraceuticals, Feed additives, Biotech, Agrochemicals, Cosmetics, and Chemical industries. In addition, the company also provides risk assessment services for evaluating the safety of Active Pharmaceutical Ingredients (API), excipients, extractable and leachable including pharmaceutical impurities resulting due to manufacturing process or degradation
of the product. VBS also provides expert services for the determination of health-based exposure limits e.g. permitted daily exposure or allowable daily exposure (ADE) including occupational exposure limits (OEL) for pharmaceutical manufacturers.

Services Offered:
a) Toxicology[2]
b) Agro-chemical and Chemical Safety[3]
c) Bio Compatibility Studies[4]
d) Diet Formulation[5]
e) Batch Release Test[6]
f) Medical Devices[7]
g) Food Additives[8]
h) Cosmetics[9]

Website BSE
  • Market Cap ₹ 18.8 Cr.
  • Current Price ₹ 29.8
  • High / Low ₹ 64.8 / 19.1
  • Stock P/E
  • Book Value ₹ 21.6
  • Dividend Yield 0.00 %
  • ROCE -4.16 %
  • ROE -14.2 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -4.25% over past five years.
  • Company has a low return on equity of -14.3% over last 3 years.
  • Debtor days have increased from 94.8 to 118 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Services Healthcare Research, Analytics & Technology

Edit Columns
Loading peers table ...

Half Yearly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2019 Mar 2020 Sep 2020 Mar 2021 Sep 2021 Mar 2022 Sep 2022 Mar 2023 Sep 2023 Mar 2024 Sep 2024
7.33 6.81 5.28 4.76 5.38 4.31 2.82 3.45 6.18 3.55 1.03
5.16 4.61 3.50 2.58 3.89 2.33 3.37 5.30 4.12 4.30 1.42
Operating Profit 2.17 2.20 1.78 2.18 1.49 1.98 -0.55 -1.85 2.06 -0.75 -0.39
OPM % 29.60% 32.31% 33.71% 45.80% 27.70% 45.94% -19.50% -53.62% 33.33% -21.13% -37.86%
0.00 0.11 0.00 0.03 0.02 0.40 0.01 0.68 0.03 0.08 0.04
Interest 0.97 0.98 1.01 1.13 1.14 1.20 2.48 3.40 2.85 2.90 2.14
Depreciation 0.41 0.78 0.61 0.65 0.66 0.66 1.31 1.36 1.54 2.95 1.69
Profit before tax 0.79 0.55 0.16 0.43 -0.29 0.52 -4.33 -5.93 -2.30 -6.52 -4.18
Tax % 31.65% 16.36% 68.75% 9.30% -106.90% 13.46% 2.08% 1.52% -0.87% -3.07% -1.20%
0.54 0.46 0.06 0.39 0.02 0.07 -2.56 -3.92 -0.54 -1.78 -2.07
EPS in Rs 0.86 0.73 0.10 0.62 0.03 0.11 -4.06 -6.21 -0.86 -2.82 -3.28
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
12.08 13.75 9.82 9.40 5.83 9.72 4.58
8.81 9.38 5.87 5.93 8.22 8.41 5.72
Operating Profit 3.27 4.37 3.95 3.47 -2.39 1.31 -1.14
OPM % 27.07% 31.78% 40.22% 36.91% -40.99% 13.48% -24.89%
0.23 0.11 0.03 0.42 0.69 0.11 0.12
Interest 1.69 1.95 2.14 2.35 5.89 5.75 5.04
Depreciation 0.71 1.19 1.25 1.32 2.67 4.50 4.64
Profit before tax 1.10 1.34 0.59 0.22 -10.26 -8.83 -10.70
Tax % 36.36% 24.63% 23.73% 40.91% 1.75% -2.49%
0.70 1.01 0.45 0.14 -10.44 -8.61 -3.85
EPS in Rs 1.11 1.58 0.71 0.14 -10.27 -3.68 -6.10
Dividend Payout % 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Compounded Sales Growth
10 Years: %
5 Years: -4%
3 Years: 0%
TTM: -52%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 14%
Stock Price CAGR
10 Years: %
5 Years: -26%
3 Years: -32%
1 Year: -42%
Return on Equity
10 Years: %
5 Years: -7%
3 Years: -14%
Last Year: -14%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 6.31 6.31 6.31 6.31 6.31 6.31 6.31
Reserves 15.94 17.16 17.61 17.70 11.20 8.89 7.32
13.25 17.37 35.97 44.86 57.16 60.95 65.82
3.51 7.74 9.74 12.53 10.04 9.25 6.20
Total Liabilities 39.01 48.58 69.63 81.40 84.71 85.40 85.65
17.90 20.76 29.39 36.12 57.22 54.15 66.63
CWIP 3.70 7.00 19.34 28.47 10.60 12.53 0.00
Investments 1.95 0.00 0.00 0.00 0.00 0.00 0.00
15.46 20.82 20.90 16.81 16.89 18.72 19.02
Total Assets 39.01 48.58 69.63 81.40 84.71 85.40 85.65

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
-1.04 2.34 6.97 5.28 -0.63 2.68
-5.73 -7.59 -22.30 -17.24 -5.91 -3.31
9.94 2.17 17.78 9.53 6.41 0.69
Net Cash Flow 3.18 -3.07 2.46 -2.43 -0.13 0.06

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 47.14 36.90 74.71 43.88 122.71 117.91
Inventory Days
Days Payable
Cash Conversion Cycle 47.14 36.90 74.71 43.88 122.71 117.91
Working Capital Days 260.76 309.52 245.32 125.03 468.30 235.45
ROCE % 8.35% 5.21% 3.77% -5.82% -4.16%

Shareholding Pattern

Numbers in percentages

1 Recently
Sep 2019Mar 2020Sep 2020Mar 2021Sep 2021Mar 2022Sep 2022Mar 2023Sep 2023Mar 2024Sep 2024Mar 2025
69.93% 69.93% 69.93% 69.11% 69.00% 69.00% 69.36% 69.36% 69.36% 69.36% 69.36% 69.36%
30.07% 30.07% 30.07% 30.89% 31.00% 31.00% 30.64% 30.65% 30.64% 30.64% 30.64% 30.64%
No. of Shareholders 275280325361412409393394388418424408

Documents

Announcements

Annual reports

DRHP

Credit ratings